Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Phase II study for antianxiety agent MN-305

March 3, 2005

Mechanisms of CB2 cannabinoid receptor antinociception

March 3, 2005

Bayer describes novel PDE9A inhibitors for Alzheimer's disease

March 2, 2005

Eisai scientists disclose the neuroprotective activity of donepezil hydrochloride

March 2, 2005

Modulators of amyloid beta levels claimed by Neurogenetics for Alzheimer's disease

March 2, 2005

Extended treatment improves tacrolimus efficacy in myasthenia gravis

March 2, 2005

Chondroitinase shows promise in the management of spinal cord injuries

March 2, 2005

Allopurinol shows promise as add-on therapy for refractory schizophrenia

March 2, 2005

Tasmar receives European approval

March 2, 2005

MEM-3454 studied in phase I trial

March 2, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...